• Mutation; VGNC; 46802; SRGAP3; Simple; p.Val850fs (c.2548dupG); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=21908323; DOI=10.1177/1040638711408064
O'Donoghue L.E., Rivest J.P., Duval D.L.
Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation.
J. Vet. Diagn. Invest. 23:780-785(2011)

PubMed=22916246; DOI=10.1371/journal.pone.0043355
Maeda J., Yurkon C.R., Fujisawa H., Kaneko M., Genet S.C., Roybal E.J., Rota G.W., Saffer E.R., Rose B.J., Hanneman W.H., Thamm D.H., Kato T.A.
Genomic instability and telomere fusion of canine osteosarcoma cells.
PLoS ONE 7:E43355-E43355(2012)

PubMed=27257868; DOI=10.1371/journal.pone.0156689
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=27197945; DOI=10.1111/vco.12192
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)

PubMed=36099278; DOI=10.1371/journal.pone.0274383
Megquier K., Turner-Maier J., Morrill K., Li X., Johnson J., Karlsson E.K., London C.A., Gardner H.L.
The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations.
PLoS ONE 17:E0274383-E0274383(2022)